Gabelli Funds LLC decreased its position in shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) by 20.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 36,187 shares of the specialty pharmaceutical company’s stock after selling 9,342 shares during the period. Gabelli Funds LLC owned about 0.07% of SciClone Pharmaceuticals worth $405,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Renaissance Technologies LLC increased its holdings in shares of SciClone Pharmaceuticals by 21.9% during the second quarter. Renaissance Technologies LLC now owns 2,540,200 shares of the specialty pharmaceutical company’s stock worth $27,942,000 after buying an additional 456,100 shares in the last quarter. State of Wisconsin Investment Board acquired a new stake in shares of SciClone Pharmaceuticals during the second quarter worth approximately $2,123,000. State Street Corp increased its holdings in shares of SciClone Pharmaceuticals by 9.8% during the first quarter. State Street Corp now owns 1,573,265 shares of the specialty pharmaceutical company’s stock worth $15,423,000 after buying an additional 139,877 shares in the last quarter. Menta Capital LLC increased its holdings in shares of SciClone Pharmaceuticals by 9.0% during the second quarter. Menta Capital LLC now owns 431,996 shares of the specialty pharmaceutical company’s stock worth $4,752,000 after buying an additional 35,660 shares in the last quarter. Finally, Virtu KCG Holdings LLC acquired a new stake in shares of SciClone Pharmaceuticals during the second quarter worth approximately $832,000. 72.80% of the stock is owned by institutional investors.
Shares of SciClone Pharmaceuticals, Inc. (SCLN) opened at $11.15 on Thursday. SciClone Pharmaceuticals, Inc. has a fifty-two week low of $8.55 and a fifty-two week high of $11.43.
WARNING: This article was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://stocknewstimes.com/2017/11/16/sciclone-pharmaceuticals-inc-scln-stake-decreased-by-gabelli-funds-llc.html.
SciClone Pharmaceuticals Company Profile
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
Want to see what other hedge funds are holding SCLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).
Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.